New Diet Improves Crohn’s Disease Symptoms

Research from Stanford Medicine and collaborating institutions has found that a short-term, calorie-restrictive diet can significantly improve physical symptoms and biological markers of inflammation in individuals with mild-to-moderate Crohn’s disease.

The findings, published on January 13, 2026, in Nature Medicine, suggest that a specific dietary intervention may offer relief for a condition that has historically lacked clear dietary guidance for patients.

The Fasting-Mimicking Diet Approach

The study focused on a fasting-mimicking diet (FMD), which involves a temporary shift to very low-calorie, plant-based meals. Participants in the FMD group followed a regimen of 700 to 1,100 calories per day for five consecutive days each month.

This cycle was repeated for three consecutive months. For the remainder of each month, participants returned to their usual diets.

Researchers observed that the diet led to noticeable improvements in symptoms for most participants and reduced key biological indicators of inflammation linked to the disease.

Study Design and Results

The national randomized controlled trial involved 97 people across the United States living with mild-to-moderate Crohn’s disease. The researchers divided the participants into two groups: 65 individuals followed the fasting-mimicking diet, while 32 individuals remained in a control group and maintained their usual eating habits.

The results demonstrated significant declines in objective markers of inflammation in biologic samples, which occurred alongside the improvement of clinical symptoms. Researchers noted that clinical benefits were apparent after just one FMD cycle.

We have been very limited in what kind of dietary information we can provide patients. This study will give physicians evidence to support recommendations in an area that patients are very curious about.

Sidhartha R. Sinha, MD, assistant professor of gastroenterology and hepatology and senior author

Medical Context and Challenges

Crohn’s disease is a chronic condition affecting approximately one million Americans. It causes inflammation in the digestive tract, which can result in abdominal pain, cramping, weight loss, and diarrhea.

Currently, steroids are the only approved therapeutic for mild Crohn’s disease, but their utility is limited by significant side effects associated with long-term use.

The Stanford investigators highlighted the inherent difficulties in studying dietary interventions. These challenges include the potential for inaccurate self-reporting of food intake by participants and the presence of the placebo effect, as participants are aware of the diet they are following.

Risks and Considerations

While the results were positive for the majority of participants, experts caution that a calorie-deficit approach is not suitable for everyone with Crohn’s disease.

Potential risks associated with such a restrictive diet include:

• Malnutrition
• Dehydration
• Unintended weight loss

Because of these risks, the research emphasizes the importance of physician guidance in implementing dietary changes to ensure patient safety.